H1 and Novo Nordisk have announced a strategic partnership focused on advancing clinical development through artificial intelligence, with the aim of improving how clinical trials are designed, managed, and executed. The collaboration will combine H1’s AI-powered platform and proprietary healthcare data with Novo Nordisk’s existing digital and AI capabilities to create AI-ready datasets and clinical development workflows intended to support more efficient research operations.
Under the agreement, Novo Nordisk will use H1’s technology to strengthen several aspects of clinical trial execution, including study design, site selection, and patient enrollment. The companies expect these capabilities to help reduce development timelines by enabling more informed decisions throughout the clinical development process.
As part of the collaboration, H1 will also acquire the rights to further develop StudyHub, Novo Nordisk’s digital and AI-enabled platform for clinical development. The platform will continue to evolve as part of H1’s broader portfolio supporting life sciences organisations with AI-driven clinical research capabilities.
Commenting on the partnership, Ariel Katz, CEO of H1, said, "In this age of AI, the way clinical trials should be executed needs to change. We are proud to partner with Novo Nordisk to enhance innovation in their clinical trials and to play an important part to bring their life-changing drugs to patients quicker."
Mishal Patel, Group Vice President, AI & Digital Innovation, R&D at Novo Nordisk, added, "H1 is the right partner for this work with its domain expertise, AI-ready proprietary data, and AI technology to advance what we have built at Novo Nordisk. This next wave of AI will help us reduce cycle times, address process inefficiencies at scale, and fundamentally improve how we select clinical trial sites and design studies, ultimately enabling better, faster decisions across the development lifecycle."
H1 provides AI-powered healthcare data and intelligence solutions that support pharmaceutical companies, health plans, health systems, and technology organisations. Through this partnership, both companies intend to further integrate AI into clinical development processes, supporting more efficient operations and accelerating the path from scientific discovery to potential regulatory approval.
Click here for the original news story.
